{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:55:08Z","timestamp":1769151308198,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Benzodiazepines are commonly prescribed in prisons amidst the controversies surrounding their potential role in causing behavioral disinhibition and aggressive behavior and their association with use and trafficking of illicit and addictive substances. The present study aimed to (1) ascertain the relationship between benzodiazepine prescription (including their dosage and duration of use) and aggressive behavior and behavioral disinhibition in prison and (2) investigate whether there was an association between benzodiazepine prescription, (including their dosage and duration of use) and using and trafficking illicit and addictive substances during imprisonment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were extracted from the electronic database of an \u201copen\u201d Swiss prison (<jats:italic>n<\/jats:italic>\u2009=\u20091206, 1379 measures) over a 5-year period (2010\u20132015). Measures included benzodiazepine prescription, duration of benzodiazepine use and mean dosage, and punishable behaviors (physical and verbal aggression, disinhibited but not directly aggressive behaviors, property damage or theft, substance-related offenses, and rule transgression). We assessed the relationship between benzodiazepine prescription and punishable behaviors after propensity score matching. Logistic regressions were also used to test the relationship of benzodiazepine use duration and dosage with punishable behaviors among participants who received benzodiazepines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After propensity score matching, benzodiazepine prescription was not significantly associated with any punishable behavior. Among detained persons who took benzodiazepines, there was no significant association of dosage and duration of use with offenses involving illicit or addictive substance use or trafficking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study did not empirically support the occurrence of increased aggressive or disinhibited behaviors or increased risk of substance abuse in detained persons who received benzodiazepines in prison. This suggests a need to reconsider restrictions in prescribing benzodiazepines in the prison setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-021-00504-5","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T20:02:30Z","timestamp":1621540950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relationship between benzodiazepine prescription, aggressive behavior, and behavioral disinhibition: a retrospective study in a Swiss prison"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-5937","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Baggio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladan","family":"Starcevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Br\u00e4ndle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Buadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Gamma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Schleifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"G\u00e9taz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Liebrenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1177\/0004867414548902","volume":"48","author":"B Albrecht","year":"2014","unstructured":"Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry. 2014;48:1096\u2013114.","journal-title":"Aust N Z J Psychiatry"},{"key":"504_CR2","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1360-0443.2010.02933.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution\u2014a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction (Abingdon, England). 2010;105:1870\u20134.","journal-title":"Addiction (Abingdon, England)"},{"key":"504_CR3","first-page":"339","volume":"25","author":"V Starcevic","year":"2017","unstructured":"Starcevic V. No role for benzodiazepines in posttraumatic stress disorder? A surplus of certainty despite scarce evidence. Austr Psychiatry Bull R Aust N Z Coll Psychiatr. 2017;25:339\u201341.","journal-title":"Austr Psychiatry Bull R Aust N Z Coll Psychiatr"},{"key":"504_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1586\/14737175.2014.963057","volume":"14","author":"V Starcevic","year":"2014","unstructured":"Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 2014;14:1275\u201386.","journal-title":"Expert Rev Neurother"},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/YIC.0b013e328105e0f2","volume":"22","author":"S Petitjean","year":"2007","unstructured":"Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007;22:292\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"504_CR6","first-page":"1037","volume":"30","author":"K TaT","year":"2015","unstructured":"TaT K, Saastamoinen LK, T\u00e4hk\u00e4p\u00e4\u00e4 S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen MS, Hietala J. Long-term use of benzodiazepines: definitions, prevalence and usage patterns\u2014a systematic review of register-based studies. Eur Psychiatry J Assoc Eur Psychiatr. 2015;30:1037\u201347.","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr"},{"key":"504_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77:295\u2013301.","journal-title":"Br J Clin Pharmacol"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.drugalcdep.2008.07.017","volume":"99","author":"E Lavie","year":"2009","unstructured":"Lavie E, Fats\u00e9as M, Denis C, Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend. 2009;99:338\u201344.","journal-title":"Drug Alcohol Depend"},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0004867418799453","volume":"52","author":"G Andrews","year":"2018","unstructured":"Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry. 2018;52:1109\u201372.","journal-title":"Aust N Z J Psychiatry"},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol (Oxford, England). 2014;28:403\u201339.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"Suppl 1","key":"504_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles, McGill U, Antony MM, Bouchard S, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive\u2013compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.","journal-title":"BMC Psychiatry"},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s11739-019-02143-y","volume":"14","author":"F Cosci","year":"2019","unstructured":"Cosci F, Nardi AE, Starcevic V, Chouinard G, Balon R. Lormetazepam in oral solution: a formulation at risk of high-dose use. Intern Emerg Med. 2019;14:1203\u20134.","journal-title":"Intern Emerg Med"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jamapsychiatry.2015.0351","volume":"72","author":"JH Krystal","year":"2015","unstructured":"Krystal JH, Stossel S, Krystal AD. Restricting benzodiazepines to short-term prescription. JAMA Psychiat. 2015;72:734\u20135.","journal-title":"JAMA Psychiat"},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JCP.0000000000000908","volume":"38","author":"AE Nardi","year":"2018","unstructured":"Nardi AE, Cosci F, Balon R, Weintraub SJ, Freire RC, Krystal JH, Roth T, Silberman EK, Sonino N, Fava GA, et al. The prescription of benzodiazepines for panic disorder: time for an evidence-based educational approach. J Clin Psychopharmacol. 2018;38:283\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"504_CR15","doi-asserted-by":"crossref","unstructured":"Rickels K, Moeller HJ. Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety. World J Biol Psychiatry. 2018;20(7):1\u20135.","DOI":"10.1080\/15622975.2018.1500031"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jcpt.12709","volume":"43","author":"D Cabelguenne","year":"2018","unstructured":"Cabelguenne D, Picard C, Lalande L, Jonker J, Sautereau M, Meunier F, Zimmer L. Benzodiazepine dose reduction in prisoner patients: 15 years\u2019 teamwork between psychiatrists and pharmacists. J Clin Pharm Ther. 2018;43:807\u201312.","journal-title":"J Clin Pharm Ther"},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF01318404","volume":"47","author":"BS Elger","year":"2002","unstructured":"Elger BS, Goehring C, Revaz SA, Morabia A. Prescription of hypnotics and tranquilisers at the Geneva prison\u2019s outpatient service in comparison to an urban outpatient medical service. Soz Praventivmed. 2002;47:39\u201343.","journal-title":"Soz Praventivmed"},{"key":"504_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/add.13877","volume":"112","author":"S Fazel","year":"2017","unstructured":"Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction (Abingdon, England). 2017;112:1725\u201339.","journal-title":"Addiction (Abingdon, England)"},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1046\/j.1360-0443.2003.00527.x","volume":"98","author":"D Borrey","year":"2003","unstructured":"Borrey D, Meyer E, Duchateau L, Lambert W, Van Peteghem C, De Leenheer AP. Longitudinal study on the prevalence of benzodiazepine (mis)use in a prison: importance of the analytical strategy. Addiction. 2003;98:1427\u201332.","journal-title":"Addiction"},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1078345814532419","volume":"20","author":"J McKee","year":"2014","unstructured":"McKee J, Penn JV, Koranek A. Psychoactive medication misadventuring in correctional health care. J Correct Health Care. 2014;20:249\u201360.","journal-title":"J Correct Health Care"},{"key":"504_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1078345813518629","volume":"20","author":"PD Pilkinton","year":"2014","unstructured":"Pilkinton PD, Pilkinton JC. Prescribing in prison: minimizing psychotropic drug diversion in correctional practice. J Correct Health Care. 2014;20:95\u2013104.","journal-title":"J Correct Health Care"},{"key":"504_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1078345811421591","volume":"18","author":"R Reeves","year":"2012","unstructured":"Reeves R. Guideline, education, and peer comparison to reduce prescriptions of benzodiazepines and low-dose Quetiapine in prison. J Correct Health Care. 2012;18:45\u201352.","journal-title":"J Correct Health Care"},{"key":"504_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1258\/rsmmsl.48.4.307","volume":"48","author":"BS Elger","year":"2008","unstructured":"Elger BS. Prisoners\u2019 insomnia: to treat or not to treat? Medical decision-making in places of detention. Med Sci Law. 2008;48:307\u201316.","journal-title":"Med Sci Law"},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0010-440X(03)00112-3","volume":"44","author":"NP Lekka","year":"2003","unstructured":"Lekka NP, Paschalis C, Papadourakis A, Beratis S. Characteristics of inmates receiving prescribed benzodiazepines in a high-security greek prison. Compr Psychiatry. 2003;44:409\u201314.","journal-title":"Compr Psychiatry"},{"key":"504_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drugpo.2015.12.007","volume":"29","author":"TM Watson","year":"2016","unstructured":"Watson TM. Prisoners\u2019 access to psychoactive medications: the need for research and improved policy. Int J Drug Policy. 2016;29:98\u20139.","journal-title":"Int J Drug Policy"},{"key":"504_CR26","first-page":"328","volume":"44","author":"M Liebrenz","year":"2016","unstructured":"Liebrenz M, Schneider M, Buadze A, Gehring M-T, Dube A, Caflisch C. High-dose benzodiazepine users\u2019 perceptions and experiences of anterograde amnesia. J Am Acad Psychiatry Law. 2016;44:328\u201337.","journal-title":"J Am Acad Psychiatry Law"},{"key":"504_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.drugalcdep.2012.09.019","volume":"129","author":"L Lundholm","year":"2013","unstructured":"Lundholm L, Hagg\u00e5rd U, M\u00f6ller J, Hallqvist J, Thiblin I. The triggering effect of alcohol and illicit drugs on violent crime in a remand prison population: a case crossover study. Drug Alcohol Depend. 2013;129:110\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"504_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pbb.2004.06.011","volume":"79","author":"B Reynolds","year":"2004","unstructured":"Reynolds B, Richards JB, Dassinger M, de Wit H. Therapeutic doses of diazepam do not alter impulsive behavior in humans. Pharmacol Biochem Behav. 2004;79:17\u201324.","journal-title":"Pharmacol Biochem Behav"},{"key":"504_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14659891.2016.1195893","volume":"22","author":"B Albrecht","year":"2017","unstructured":"Albrecht B, Staiger PK, Best D, Hall K, Nielsen S, Lubman DI, Miller P. Benzodiazepine use of community-based violent offenders: a preliminary investigation. J Subst Use. 2017;22:295\u2013303.","journal-title":"J Subst Use"},{"key":"504_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/ijcp.12362","volume":"68","author":"A Bartlett","year":"2014","unstructured":"Bartlett A, Dholakia N, England R, Hales H, Ev H, McGeorge T, Moss B, Ovaisi S, Tukmachi E, Patel S. Prison prescribing practice: practitioners\u2019 perspectives on why prison is different. Int J Clin Pract. 2014;68:413\u20137.","journal-title":"Int J Clin Pract"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00504-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T20:04:34Z","timestamp":1621541074000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00504-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for conducting the study was received from the Cantonal Research Ethics Committee of Bern (no. 2016-01539).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}